Publications by authors named "Philip D Leming"

Claim this Profile
A
A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and Physicians.
William L Barrett, Philip D Leming, Jillian Hunt, Andrew Guinigundo, Lana Uhrig

J Cancer Educ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.
Mohammed Kashani-Sabet, Sancy A Leachman, Jennifer A Stein, Jack L Arbiser, Elizabeth G Berry, Philip D Leming

JAMA Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, Philip D Leming

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Douglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, Michael A Marchetti, Megan Othus, Philip D Leming

JAMA Dermatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, Philip D Leming

JAMA Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.
Mariah M Johnson, Sancy A Leachman, Lisa G Aspinwall, Lee D Cranmer, Clara Curiel-Lewandrowski, Philip D Leming

Melanoma Manag· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, Philip D Leming

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
Craig L Slingluff, Sandra Lee, Fengmin Zhao, Kimberly A Chianese-Bullock, Walter C Olson, Philip D Leming

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, Philip D Leming

N Engl J Med· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis